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IN THE NEWS
SCIENCE OVER POLITICS: WHY THE FDA MUST
ALLOW PLAN B AS A NONPRESCRIPTION DRUG
Samantha Dietle*

On April 5, 2013, the United States District Court
for the Eastern District of New York held that the
Food and Drug Administration (FDA) had 30 days to
allow the sale of Plan BI without a prescription and
without age or point-of-sale restrictions.2 The court
had previously given the agency a chance to allow
Plan B to have nonprescription status regardless of
age without a mandate from the court, 3 but the FDA
not only refused to revise its decision on the drug's
status, but also failed to provide sufficient evidence
to support its decision. The fight over the approval of
Plan B for over-the-counter sale seems to be the result
of politics rather than scientific evidence, as evidence
suggests that Plan B is safe for use by all women
of childbearing age yet the FDA has continuously
imposed age-based and point-of-sale restrictions.
Plan B is an emergency contraceptive pill that can be
taken by a woman up to 72 hours after unprotected
sex or birth control failure.' The side effects of Plan
B are mild and similar to the side effects associated
with regular birth control pills, including menstrual
cycle changes and nausea. These mild side effects
make Plan B safer than other drugs that are currently
approved for over-the-counter sale that rely labeling
for safe use of the drug, without any point of sale
or age restrictions.6 Before a drug is approved for
sale to consumers, the manufacturer submits a new
drug application (NDA) to the FDA.7 After a NDA
is approved, if a drug manufacturer wants to make
the drug available for additional indications, thus
making the drug available to more individuals, the
manufacturer must submit a supplemental new drug
application (SNDA). 8 When considering whether
to approve an NDA or SNDA, the FDA looks at
evidence of the drug's safety and effectiveness in
light the indicated use(s) of the drug.9 When the

FDA initially approved Plan B as an emergency
contraceptive, it was approved for women eighteen
years of age and older without a prescription but a
prescription was required for women under eighteen
years of age. The practical effect of this decision
was that point-of-sale restrictions were necessary, as
women were required to show identification to prove
their age before purchasing Plan B and point of sale
restrictions were enacted by selling Plan B behind the
pharmacy counter.10
After receiving the initial approval of Plan B, the
manufacture was unable to obtain a change in the
status of the drug until the court intervened. The
manufacturer of Plan B submitted three different
SNDAs in an attempt to change the status of Plan B.
First, the manufacture attempted to expand access to
all ages without requiring a prescription or imposing
point of sale restrictions, but the FDA rejected the
SNDA. Second, the manufacture attempted to expand
access to all women sixteen years of age and older
without prescription but this SNDA was also rejected
by the FDA. Third, the manufacturer attempted to
expand access to all women seventeen years of age
and older without a prescription yet again the FDA
rejected the SNDA. 1' In 2009, however, the court
forced the FDA to expand access to Plan B without
a prescription to all women seventeen years of age
and older. The court also remanded the issue back
to the FDA so that the agency could determine
whether available information on the safety of
Plan B warranted making additional changes to
the drug's status. 12 Specifically, the court indicated
that the FDA should consider the status of Plan B,
utilizing the agency's general policies for approving
drugs for over-the-counter sale rather than political
considerations. 13
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The FDA denied the SNDA and citizen petition, a
petition to change a drug's status made by the public,
requesting to change the status of Plan B making
available to women of all ages without a prescription,
based on Secretary of Health and Human Services
Kathleen Sebelius's Order. A December 2011
memorandum to the Commissioner of the FDA, Dr.
Margaret Hamburg, detailed Secretary Sebelius's
justification for declining to switch Plan B to over-thecounter status. 14 Secretary Sebelius's involvement
and disagreement with the FDA Commissioner
was unprecedented, Secretary Sibelius effectively
overruled a decision by the FDA despite strong
scientific evidence supporting the FDA's position. The
FDA analyzed Secretary Sebelius's memorandum
attempting to justify the denial of over-the-counter
status to Plan B without age restrictions and found
little evidence in support of her position, which lead
the court to conclude that her position was focused on
the political consequences of allowing unrestricted
access to Plan B rather than scientific evidence.
There are number of issues with Secretary Sebelius's
justifications for declining to make Plan B available to
all women over-the-counter. First, as she argued that
the data related to label comprehension and actual
use did not account for women of all age ranges to
which Plan B would be available if the drug were
available over-the-counter without point of sale or
age restrictions. 15 However, the FDA had previously
waived the requirement that the studies include
participants between the ages of eleven and thirteen
because the use of Plan B by girls in this age range is
rare and the number of participants in this age range
included in the studies would have been so small as
to be unrepresentative.16 Second, Secretary Sebelius
pointed to cognitive and behavioral differences
between older and younger adolescents as a relevant
factor in denying access to Plan B as an over-thecounter drug to women of all ages.17 The Director
of the Office of New Drugs at the FDA, however,
determined that cognitive and behavioral differences
between older and younger adolescents did not
address whether the younger girls of reproductive
age can safely understand and use Plan B but rather
whether the younger girls of reproductive age should
be engaging in the types of sexual behavior that
necessitate the use of Plan B;18 the latter issue is not
an issue that the FDA is designed to regulate as the

role of the FDA is to determine whether a drug is
safe and effective for its intended use. Furthermore,
if the issue is that younger reproductive age girls may
not be able to comprehend the labeling and usage of
Plan B, in the past, data establishing such claims has
never been required as part of a drug's approval for
over-the-counter status.." Finally, Secretary Sebelius
failed to identify the harm associated with making
Plan B available to all women of reproductive age
given that the FDA typically approves drugs for overthe-counter sale without requiring the manufacture
to show that the drug is safe for the youngest
populations.2 0 The likelihood of unsafe use, abuse, or
misuse of Plan B is extremely low, especially when
compared to the risks associated with other more
dangerous drugs 21 that are currently sold over-thecounter without any restrictions.
The same day that Secretary Sebelius sent the
memorandum justifying the denial of the SNDA for
Plan B, Commissioner Hamburg released her own
statement2 2 explaining that the scientific data used
by the Center for Drug Evaluation and Research
(CDER) supported the finding that Plan B could
be safely used by all women of childbearing age
and that the role of the FDA was to approve drugs
based scientific evidence regarding the drug's safety
and efficacy for its intended use. 23 Commissioner
Hamburg went on to note that, "following Secretary
Sebelius's direction" 24 the FDA had to deny the
SNDA for non-prescription access to Plan B for
women under seventeen years of age, despite the
FDA's typical approval process and evidence of Plan
B's safety that she acknowledged in the rest of her
statement.
In reviewing the FDA's actions in denying the citizen
petition 25 to remove point-of-sale and age restrictions
on Plan B, the court looked to whether the agency's
actions were "arbitrary, capricious, an abuse of
discretion or otherwise not in accordance with the
law."26 This standard is deferential to the agency,27 but
the court determined that the unprecedented nature
of Secretary Sebelius's involvement, 28 particularly its
disregard of the FDA's standards and typical practices
for switching a drug's status and the secretary's lack of
technical expertise, made the FDA's decision denying
the SNDA arbitrary, capricious, and unreasonable. 29
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It seemed clear to the court that there was no
scientific justification for the age or point-of-sale
restrictions and, therefore, the denial of the citizen
petition was reversed; the FDA was given thirty days
to allow access to Plan B as a nonprescription drug
and the issue was remanded to the FDA to make
any necessary labeling changes or changes based
on the different available doses of Plan B. 30 The
court's decision looked past the potential political
consequences of allowing women of all ages to
access a contraceptive designed for use after sex and
upheld the FDA's role as a regulator of the safety and
efficacy of drugs based on science. The court was
appropriately deferential to the FDA and provided the
FDA with an opportunity to use scientific evidence to
justify its age and point-of-sales based restrictions on
Plan B, but as seen through the analysis of Secretary
Sebelius's justification for the restrictions on the
sale of Plan B, the science simply did not support
the restrictions that the FDA placed on the sale of
Plan B. By maintaining the FDA's standards and
typical procedures for decisions to allow drugs to be
available over-the-counter, the court has reinforced
the idea that an agency's technical determinations
should be based on scientific evidence, insulated
from political influence, to prevent inconsistent or
unjustifiable results.
I Plan B, also known as the "morning-after pill", is used to
refer to Plan B One-Step, the specific one-pill dosage type at
issue in this case; however, there is no meaningful difference
between this type of Plan B and other forms aside from the
number of pills that need to be taken for the drug to work
effectively.
2 Tuimmino v. Hambwg, No. 12 CV 763 (ERK)(VVP), 2013
U.S. Dist. WL 1348656, at *31 (E.D.N.Y 2013).
3 Tummino v. Torti, 603 E Supp. 2d 519, 550 (E.D.N.Y.
2009).
4 Plan B One-Step (levonorgestrel): About. http://www.
planbonestep.cosm/about-plan-b-one-step.aspx (last accessed
Apr. 12, 2013) (explaining that Plan B is not to be used as
a regular form of birth control but rather it is to be used
as a back-up form of contraceptives when another form
contraception fails).
5 Plan B One-Step (levonorgestrel): FAQs. http://www.
planbonestep.com/faqs.aspx (last accessed Apr. 12, 2013).
6 Tummino, WL 1348656 at * 15 (examining other drugs
that are approved for over-the-counter sale that pose a more
significant risks to users under the age of 18 than Plan B,
including cough syrup that contains dextromethorphan that
poses high risk of abuse by teens, and acetaminophen, which
is frequently ingested in high doses by individuals attempting
to commit suicide).
21 U.S.C §355(b)(1) (2010).

1 21 U.S.C. §§ 355(b)(4)(A)-(B) (2010).
9 U.S. Food and Drug Admin., Comm'r Statement, Statement
from FDA Comm r MargaretHamburg, M.D. on Plan B OneStep (Dec. 7, 2011) [hereinafter Hamburg Statement] http://
www.fda.gov/NewsEvents/Newsroom/ucm282805.htm (last
accessed Apr. 12, 2013).
'o Alastair J.J. Wood, M.D et al., The Politics of Emergency
Contraception,366 New Eng. J. Med. 101, 101-02 (2012)
www.nejm.org/doi/full/10.1056/NEJMpl 114439 (last
accessed Apr. 12, 2013).
1 Tummino v. Torti, 603 F. Supp. 2d 519, 523 (E.D.N.Y
2009).
12 Id. at 550.
13 Id. at 548 (concluding that the FDA has not presented any
evidence to rebut the assertion that it was acting in bad faith
and in response to political pressure in its review of the status
of Plan B).
14 Memorandum from Kathleen Sebelius to Margaret
Hamburg, M.D. Comm'r of Food and Drugs (Dec. 7, 2011)
[hereinafter Sebelius Memo] http://www.hhs.gov/news/
press/20 I pres /12/201 11 207a.pdf (last accessed Apr. 12,
2013).
15 Id.
'6 Tummino v. Hamburg, 2013 U.S. Dist. WL 1348656,
at *7-*8 (E.D.N.Y 2013) (noting that Secretary Sebelius'
disagreement over granting an age waiver for the study was
not a valid reason to effectively overrule the FDA's decision).
1 Sebelius Memo, supra note 14.
" Tummino. WL 1348656 at *8.
11 Id. (noting that the FDA has never precluded the over-thecounter sale of drugs based on this reasoning).
20 Id. at *9 (noting that the FDA approves drugs for overthe-counter status without such data, relying on labeling to
effectively indicate age-based restrictions).
21 Id. (explaining that the reasoning offered would require
removal of over-the-counter status for drugs containing
dextromethorphan, laxatives, analgesics, and acetaminophen).
22 U.S. Food and Drug Admin., Comm'r Statement,
Statementfom FDA Comm'r Margaret Hamburg,M.D.
on Plan B One-Step (Dec. 7, 2011). http://www.fda.gov/
NewsEvents/Newsroom/ucm282805.htm (last accessed Apr.
12, 2013).
23 Id. (discussing the review of scientific evidence and
risk/benefit assessment conducted to reach the conclusion
that Plan B One-Step met the regulatory standard for a
nonprescription drug).
24 Id.
25 Tummino, WL 1348656 at * 19 (noting that the Court
had jurisdiction over the citizen petition and not the SNDA;
however, the two are related because once Secretary Sebelius
directed the FDA to deny the SNDA, there was no basis to
approve the citizen petition as the same data was relied on for
both applications).
26 Id. (citing the Administrative Procedure Act 5 U.S.C. §
706(2)(A)).
27 Id. at *20.
28 Alastair J.J Wood, M.D et al., The Politicsof Emergency
Contraception, 366 New Eng. J. Med. 101, 101-02 (2012)
www.nejm.org/doi/full/10.1056/NEJMpi 114439 (last
accessed Apr. 12, 2013) (discussing Secretary Sebelius's
decision to overrule the FDA on Plan B and indicating
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that it was the first time the Secretary of the United States
Department of Health and Human Services had ever
overruled a regulatory decision on drug approval that was
made by the FDA).
28 Alastair J.. Wood, M.D et al., The Politics of Emergency

Contraception,366 New Eng. J. Med. 101, 101-02 (2012)
www.nejm.org/doi/full/1 0.1056/NEJMp 1114439 (last
accessed Apr. 12, 2013) (discussing Secretary Sebelius's
decision to overrule the FDA on Plan B and indicating
that it was the first time the Secretary of the United States
Department of Health and Human Services had ever
overruled a regulatory decision on drug approval that was
made by the FDA).
29 Tunimino, WL 13648656 at *22.
30 Id. at *31.
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